Day 1

• Plasma-derived medicines (PDMPs) are essential for some 300,000 patients across the EU who rely on these therapies every day to treat a variety of rare, chronic, and life threatening conditions. Without these treatments, many patients would have a substantially diminished quality of life, and some may not survive.
• PDMPs are a finite resource because the manufacture of these medicines is dependent on the amounts of human plasma collected.
• Using the AIFA CTS Innovation Algorithm and the WHO Framework for Appropriate Medical Use, a broad range of Key Opinion leaders, in the field of immunology, neurology, rheumatology and dermatology, debated about the appropriate use of Immunoglobulins for their patients. The discussion
  was concluded in a Green Paper developed by Vintura.

 Maarten Van Baelen, Executive Director, Plasma Protein Therapeutics Association

• Robust RWE generation to accelerate drug approval and inform clinical practice during a rapidly
  evolving pandemic
• COVID-19 and the wide-ranging role of RWE in informing decision making: From disease monitoring to
  treatment effectiveness
• Methodological considerations and cautionary tales of RWE generation in COVID-19
• Best practices and lessons learned for effectively utilizing RWD/RWE in future pandemics

 Stephane Read, Sr Technical Consultant, Epidemiology, Certara Evidence & Access

• Recognize the potential of Personalized Medicine in Oncology / Cancer Patients benefits;
• Identify challenges which could be encountered during HTA process;
• Develop strategies to overcome or to remove any barrier for Patient Access to Precision Oncology